HC Wainwright Has Optimistic Outlook of INO FY2024 Earnings

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) – HC Wainwright lifted their FY2024 earnings per share estimates for Inovio Pharmaceuticals in a report released on Monday, November 18th. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will post earnings of ($4.39) per share for the year, up from their previous estimate of ($4.64). HC Wainwright currently has a “Neutral” rating and a $5.00 price target on the stock. The consensus estimate for Inovio Pharmaceuticals’ current full-year earnings is ($4.45) per share. HC Wainwright also issued estimates for Inovio Pharmaceuticals’ Q4 2024 earnings at ($1.03) EPS, Q1 2025 earnings at ($1.08) EPS, Q2 2025 earnings at ($0.90) EPS, Q3 2025 earnings at ($0.78) EPS, Q4 2025 earnings at ($0.68) EPS and FY2025 earnings at ($3.35) EPS.

INO has been the subject of several other research reports. Royal Bank of Canada dropped their price objective on shares of Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating for the company in a research note on Friday, November 15th. Oppenheimer dropped their price target on shares of Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating for the company in a research note on Monday. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $38.00.

Inovio Pharmaceuticals Stock Up 2.3 %

Inovio Pharmaceuticals stock opened at $4.06 on Wednesday. The company has a fifty day simple moving average of $5.61 and a 200-day simple moving average of $8.00. Inovio Pharmaceuticals has a 52-week low of $3.85 and a 52-week high of $14.75.

Hedge Funds Weigh In On Inovio Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Cornercap Investment Counsel Inc. acquired a new position in Inovio Pharmaceuticals during the 2nd quarter worth $184,000. Bank of New York Mellon Corp purchased a new position in Inovio Pharmaceuticals during the 2nd quarter worth $661,000. American Century Companies Inc. raised its holdings in shares of Inovio Pharmaceuticals by 62.2% in the second quarter. American Century Companies Inc. now owns 31,565 shares of the biopharmaceutical company’s stock valued at $255,000 after buying an additional 12,100 shares during the last quarter. Signature Estate & Investment Advisors LLC acquired a new stake in shares of Inovio Pharmaceuticals during the second quarter worth about $88,000. Finally, Dimensional Fund Advisors LP purchased a new position in shares of Inovio Pharmaceuticals during the second quarter worth about $605,000. 26.79% of the stock is currently owned by institutional investors and hedge funds.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.